SpermCheck Vasectomy is one of several products founded on technology developed by John C. Herr, director of the University of Virginia's Center for Research in Contraceptive and Reproductive Health, and patented and licensed by the University of Virginia Patent Foundation.
"The SpermCheck Vasectomy test is the result of many years of basic science research coupled with clinical chemistry know-how", stated John C. Herr, a professor in University of Virginia's Department of Cell Biology, citing interdisciplinary clinical collaborations with Drs. Stuart S. Howards, professor of urology, and Charles J. Flickinger, professor emeritus of cell biology. "Similar to a home pregnancy test for women, it is the first immunodiagnostic test with the sensitivity and specificity required to detect low numbers of sperm, and it is the first immunodiagnostic test to receive FDA approval for monitoring sperm count after vasectomy."
The device gives men an opportunity to test their post vasectomy fertility status at home rather than return to the physician's office or a laboratory with semen samples, as has traditionally been required to confirm sub-fertile sperm levels.
"We are very excited that one of our faculty start-ups is about to introduce its first product to the market", stated Robert S. MacWright, executive director of the University of Virginia Patent Foundation. "Through an enlightened and balanced integration of basic science and practical application in his research, Dr. Herr is delivering important scientific knowledge that is truly serving the public good."
Approximately 500.000 men undergo vasectomies in the United States each year, making vasectomy the third-most-popular contraceptive option among married couples in the United States, according to the National Institutes of Child Health and Human Development, a division of the National Institutes of Health (NIH). Also according to the NIH, one in six men over age 35 have had a vasectomy.
It is widely reported that vasectomies are not 100 percent effective, and vasectomized men can experience recanalization, or the spontaneous healing or restoration of the vas deferens resulting in fertility. SpermCheck Vasectomy, to be made available as soon as spring 2008 by ContraVac Inc., can be used to monitor and confirm sterility following the vasectomy procedure, alerting couples should fertility become restored. In addition, Dr. Herr posited, the device could be used to monitor male infertility over time in the event that male contraceptive pills are successfully developed.
Over 17 years, Dr. Herr's lab worked to identify a gene (ACRV1) that encoded a protein that could serve as a sperm-specific biomarker. This protein SP-10 is very soluble and highly expressed, making it an ideal target for diagnostic testing, as in the SpermCheck Vasectomy home-use test developed by the University of Virginia start-up ContraVac Inc. The device uses monoclonal antibodies that bind specifically to the SP-10 protein to measure the amount in nanograms of SP-10 protein present, which directly correlates to the number of sperm present.
"Translational research is essential to bringing the exciting new developments in basic-science biomedical research to patients", Dr. Howards stated. "The outcome of an intense collaboration between basic science and clinical urology, SpermCheck Vasectomy is an example of translational research 20 years in the making."
The University of Virginia Patent Foundation is a not-for-profit corporation that serves to bring University of Virginia technologies to the global marketplace by evaluating, protecting and licensing intellectual property generated in the course of research at the University of Virginia. The Patent Foundation reviews and evaluates over 175 inventions per year and has generated nearly $85 million in licensing revenue since its formation in 1978.
For more information about SpermCheck Vasectomy, you can visit the ContraVac website.